Previous studies have suggested that the GPX1-200Leu variant has about 10% lower GPX activity than the wild-type enzyme [24] and that the frequency of the Leu allele is strongly associated with the risk of cancer, such as lung cancer, breast cancer, meningioma, and prostate cancer [25]–[29]. This evidence concerns the gene GPX1 and prostate carcinoma.